Divi's Laboratories Q4 Results: Divi's Laboratories announced its January-March quarter results for fiscal 2023-24 (Q4FY24) on Saturday, May 25, reporting a rise of 67.6 per cent in net profit at ₹538 crore, compared to ₹321 crore in the corresponding period last year.
The pharma major's revenue from operations in the fourth quarter of FY24 rose 18 per cent to ₹2,303 crore, compared to ₹1,951 crore in the year-ago period.
Also Read: Q4 Results Today: Aurobindo Pharma, Reliance Power, Divi's Lab among 91 companies to post earnings on May 25The dividend is subject to the approval of the company's shareholders.
Margin rose to 32 per cent compared to 25 per cent in the year-ago period.
According to the latest BSE rejig, Divi's Laboratories will be added to the Sensex Next 50 index.
Divi's Laboratories Q4 Results: Divi's Laboratories announced its January-March quarter results for fiscal 2023-24 (Q4FY24) on Saturday, May 25, reporting a rise of 67.6 per cent in net profit at ₹538 crore, compared to ₹321 crore in the corresponding period last year.
The pharma major's revenue from operations in the fourth quarter of FY24 rose 18 per cent to ₹2,303 crore, compared to ₹1,951 crore in the year-ago period. The company's board also recommended a final dividend of 1,500 per cent i.e., at ₹30 per equity share for the face value of ₹2 each for fiscal ended March 31, 2024.
Also Read: Q4 Results Today: Aurobindo Pharma, Reliance Power, Divi's Lab among 91 companies to post earnings on May 25
The dividend is subject to the approval of the company's shareholders. The company's 34th annual general meeting (AGM) will be held on August 12, 2024. The record date for the purpose of the payment of dividend is August 2, 2024.
At the operating level, Divi's Labs earnings before interest, tax, depreciation and amortization (EBITDA) in the March quarter rose 50.1 per cent to ₹731 crore, compared to ₹487 crore in the same period last year. Margin rose to 32 per cent compared to 25 per cent in the year-ago period.
The board approved the appointment of Dr. Rajendra Kumar Premchand, as an additional director designated as independent director of the company, for a term of five years commencing from May 25, 2024.
The board also approved the re-appointment of Dr. Murali K. Divi as the managing director for a further period of five years, upon the expiry of his present term of office, i.e. with effect from October 10, 2024, and payment of remuneration.
The Hyderabad-based multinational pharma company is a producer of active pharmaceutical ingredients, custom synthesizes generic APIs and intermediates. According to the latest BSE rejig, Divi's Laboratories will be added to the Sensex Next 50 index. On Friday, shares of Divi's Laboratory settled 0.30 per cent higher at ₹4,122.75 apiece on the BSE.
Milestone Alert! Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.
You are on Mint! India's #1 news destination (Source: Press Gazette). To learn more about our business coverage and market insights Click Here!
